Treatment of Multifocal Lung Adenocarcinoma
To gather preliminary safety and outcome data for the multimodality treatment of lung adenocarcinoma in the setting of multifocal BAC.
Checked against the public recordLast updated Nov 20, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Mayo Clinic
- Interventions being studied
- Genetic: Multifocal Lung Adenocarcinoma
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
* Patient must be \> 18 years of age * Two or more GGO's or solid lesions suspicious for multifocal disease. * Clinical diagnosis of N0 * No evidence of distant metastases * No prior intra-thoracic radiation therapy (NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted.), previous chemotherapy, or surgical resection for non-small cell lung cancer (NSCLC). * No other cancer in the past 5 years except early stage prostate cancer, or basal cell of skin. * PFT's that show patient is capable of tolerating a lung resection. * Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study. * Patient must be able to understand and willing to sign an IRB-approved informed consent document.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic in RochesterRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 20, 2025. Always confirm current availability with the study team.